CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort
Open Access
- 1 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica
- Vol. 140 (3), 405-407
- https://doi.org/10.1007/s00401-020-02169-z
Abstract
No abstract availableFunding Information
- Deutsche Kinderkrebsstiftung (DKS 2006.03, 2009.19, 2011.01, 2014.17)
This publication has 12 references indexed in Scilit:
- CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomasNeuro-Oncology, 2019
- Integrated molecular characterization of IDH‐mutant glioblastomasNeuropathology and Applied Neurobiology, 2018
- MRI Phenotype of RELA-fused Pediatric Supratentorial EpendymomaClinical Neuroradiology, 2018
- Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5Science, 2016
- Supratentorial ependymomas of childhood carry C11orf95–RELA fusions leading to pathological activation of the NF-κB signaling pathwayActa Neuropathologica, 2014
- C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymomaNature, 2014
- Molecular Staging of Intracranial Ependymoma in Children and AdultsJournal of Clinical Oncology, 2010
- Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymomaGenes, Chromosomes and Cancer, 2008
- Chromosomal Abnormalities Subdivide Ependymal Tumors into Clinically Relevant GroupsThe American Journal of Pathology, 2001
- CDKN2A/p16 in ependymomasJournal of Neuro-Oncology, 2001